Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Meanwhile world quadrant are closing their short position.
Voleon lost a good bit going short in Novacyt around 350 to 400p level peaking to 1.2% in end Sept. They closed in oct around 500 to 550 level
https://shorttracker.co.uk/company/GB00BJL5BR07/
Sorry first link is wrong
https://www.ox.ac.uk/news/2020-09-25-evaluation-lampore-rapid-tests-covid-19-show-high-levels-diagnostic-sensitivity#
https://www.google.co.uk/amp/s/www.dailymail.co.uk/news/article-8857535/amp/Government-secures-20-million-game-changing-15-minute-Covid-19-swab-kits.html
Interactive Investor deadline time to take up offer before midnight 27/10/20
When company announced they were placing £80 million worth shares with current institutional holders there was a huge hue and cry by the share holders that they were sidelined and a substantial part of this offer should have been given to them.
When we now see current PI waiting till last minute to see what the price will be on 28th to take up the small 1:37 offer it is baffling. We should be thankful institutions overwhelmingly took the offer instantly to shore up £80 million for the company's vital future work. If price went below 175p the £7 million will not be raised surely from the PI.
Happy to note many want to take up the offer no matter what the price will be on the 28th October. Well done from the company and future share price point of view.
So perhaps we need to look at large placing from a practical point of view at raise much needed cash in one go. Just a thought.
They ain't sellers the TR1 reflects the voting rights % based on current outstanding shares. So no worry there.
If you see the New TR1 today and the old one from 6.10.20 you will note Bong Koh and Nimish Shah holds exactly the same149433442 shares.
However at the bottom of the holding the 6th October TR1 states total shares 149M and the latest today says 164M. Hence the artificial drop in voting rights . Not selling.
TR1 Today
All percentages are based on the notified current issued share capital of Synairgen plc of 164,910,914 ordinary shares.
Old TR1 6th October
All percentages are based on the notified current issued share capital of Synairgen plc of 149,433,442 ordinary shares.
Good results Ken as you noted about SoftCat. Bought some at 1107p at the drop for near term hold. MMs playing games as dont see any major negative and dividend reinstated.
Man they had whopping special dividend last year when it was around 850p
Good to know details Ken. Tough to sit on cash. You can consider buying a small lot of softcat Plc. SCT. They will do well with work from home and cloud computing in the new world we live in. Had dropped 10% from sept high and shorts closed. Results tommorow. May give you a 5% fillip tommorow. Good for 1500p by December. You pay 0.5 stamp.
Day yes forgot to add which you did-Synairgen phase 3 trial in 20 countries will hasten recruitment and publicity.
Scoop if phase 3 results are good demand will come from all parts of the world not just USA including Britain then asking this another gem of UK company to help unlock the lockdown (worlwide) with a good viable early treatment option. Numis put a figure in such a scenario at £50.
SHOWS up like this
Action required before midday on 28th Oct 2020.
Synairgen wants to raise approximately £87 million (before expenses) to fund its phase III trial of one of its novel therapies in COVID-19 patients, scale up its manufacturing activities, and strengthen its balance sheets. To help do this, the company is giving existing shareholders the chance to buy an extra 1 share for every 37 shares held at the close of business on 14 October 2020.
You can choose now if you’d like to take up this entitlement to buy extra shares.
The easiest way to do this is online, and the deadline to give an instruction is noon on Wednesday 28 October 2020.
You have two options
1. Do nothing
You don’t have to take part in this Open Offer. If you don’t, we’ll remove your entitlements when the offer is finished. No cash will be paid in respect of unused entitlements.
2. Buy new shares
You can use your entitlements to buy new shares. The new shares cost 175p each.You may apply for more shares than this, also at 175p, but you may not receive all the shares you apply for.
If your entitlements are in an ISA / LISA, you can buy the new shares in your ISA / LISA or a HL Fund & Share Account. Otherwise you can only buy new shares in the account where you currently hold Synairgen shares.
Make sure the cash you need to buy shares is in your available balance by noon on Wednesday 28 October 2020 and remains there until we debit the cash, expected 29 October 2020. If there’s not enough cash we’ll only apply for as many shares as your available balance allows.
Your new shares are expected to be credited to your portfolio on, or around 4 November 2020.
Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.
You currently hold XXXX shares.
Please select an option for your HL Stocks & Shares ISA. If you have any questions please call our Investment Helpdesk on 0117 900 9000.
If you enter more than one instruction please note only the most recent will be accepted and any previous instructions will be disregarded.
Take up my basic entitlement only
Take up MORE than my basic entitlement (specify quantity including basic)
Take up LESS than my basic entitlement (specify share quantity)
If your instruction requires further detail please supply here
Gentlemen (and any ladies) we are in the world of electronic fully automated trading.
All allotments of rights are done electronically with all monies collected towards these shares going electronically including any refunds if you oversubscribed and dont get your additional allocation.
So all your ISA and ordinary share trading accounts are separate and not linked in any way and brokerage firm cannot change allocation as it is not linked to the company register on the cutoff date for your allocation of your entitlement.
So just like the Interactive investor information I sent under the heading here is the simar one from
HARGREAVES LANSDOWN
If your entitlements are in an ISA / LISA, you can buy the new shares in your ISA / LISA or a HL Fund & Share Account. Otherwise you can only buy new shares in the account where you currently hold Synairgen shares.
This is how you will see the details if you go into CORPORATE ACTION section of your account and click the see Action button
It will show "Action required"
Note - you cannot transfer your offer outside ISA or designated account see below
SYNAIRGEN NEW ORD GBP0.01 (SUB SHS CL
Event Type
Open Offer
Description
Open Offer
Ex-entitlement Date: 15th October 2020
Rights ratio: 1-for-37
Subscription ratio: 1-for-1
Exercise price: GBP 1.75 per new share
New shares: 4th November 2020
Synairgen has announced an Open Offer; your account has been issued with 1 non-transferable subscription share for every 37 shares held. Your options are:
OPTION 1: Do nothing (Default). Your subscription shares will lapse if you do not exercise them by our deadline date.
OPTION 2: Exercise your subscription shares in full or in part. Under the terms of the open offer, each subscription share entitles you to 1 new share in Synairgen at GBP 1.75 per share.
OPTION 3: If you have exercised all your subscription shares on option 2, you may also apply for additional shares. Excess applications may be subject to scaling back. Refunds resulting from this are generally received back from the company within 2 weeks.
If your sub shares are held within an ISA account, please be aware that the sub shares are not transferable and therefore the facility to take this Offer up outside of an ISA account is unavailable.
Entitlement
xxxxxx shares
Latest Response Date
23:59 27/10/2020
Option
Allocation
Do Nothing (Default)
BOX TO CLICK
Exercise subscription shares
BOX TO ENTER HOW MANY YOU WANT
Apply for additional shares
BOX TO ENTER HOW MANY MORE YOU NEED
Once you enter the amount of shares it will take you to next page to confirm
Billy our only hope is good therapeutics that will help us to open up. 2 doses of vaccine getting out to at least half the population with cold chain factor and administering it is a mammoth task. Getting flu vaccine this winter is already a struggle due to shortage.
So without pushing Synairgen therapeutic like the SNG001 interferon delivered direct to lung without side effect is one of the best option as of now in the absence of anything till you really are ill. Something like the interferon nasal drops tried on medicos in China nonrandomised. Treating early and helping body fight the virus early is best option while really effective vaccine comes along in mid 2021. Any vaccine before that is election pressure or a weak vaccine. Unless you infect a person deliberately with covid you cannot say a vaccine works in a 6 to 9 month trial large scale. We know this from all vaccine for major viral disease is concerned. From our own point of view being at very high risk in front line we pray for an effective medication to be readily available if we get the covid.
When a share price does a 50% rise in less than a week nobody curses the Market Makers. However when it drops down everybody is up in arms.
No stock goes in a straight line and when it does without fundamentals to back it it will fall.
A gradual rise is best from long term point of view for Novacyt with its great potential for next 6 months, rather than pump and dump. Last leg remember shot to £5 and back to £2.15. May happen now to £6 level if drop is fast. Long term holders will stay calm. New casino investors who bought at top will make the noise.
Synairgen Numis reportToday 20:34
Numis
Synairgen (Buy, TP: 990p) World-class asset to treat SARS-CoV-2
Synairgen has developed an inhaled version of interferon-beta (SNG001), that has recently proven highly effective for the treatment of SARS-CoV-2 (COVID-19) in a gold-standard, placebo-controlled Phase 2 study conducted across leading respiratory centres in the UK. The drug is widely known to enhance the innate immune response, which is the body's first line of defense against viruses, and is unique in being delivered directly into the lungs, where respiratory viruses initally take hold.
Subject to funding we expect a pivotal trial to start before the end of the year, and if the Phase 2 data is replicated in a larger Phase 3 study, SNG001 would be the most effective treatment for SARS-CoV-2 with future potential to treat various seasonal, endemic, and pandemic threats.
We initiate coverage with a Buy rating and 990p price target (6x upside) derived from a base (70%)/bear (30%) scenario analysis, which in our view represents a very compelling risk/reward proposition.
Download World-class asset to treat SARS-CoV-2
(36 pages)
Prospects have been transformed: The ongoing SARS-CoV-2 pandemic has demonstrated the threat posed by respiratory viruses. In a matter of months, capabilities have evolved to be able to test for, track and isolate infected patients to protect the vulnerable, yet numbers of cases, hospitalisations and sadly deaths, are still rising. We expect this capability will be retained, and that a therapeutic market and infrastructure for identifying and treating SARS-CoV-2 (and other respiratory viruses) has been rapidly created, that could be worth $20bn/year, a fraction of the costs of global lockdown.
Innately attractive: The innate immune response is known to weaken with age and illness (Source: WHO). The elderly and those with underlying conditions are the most vulnerable to SARS-CoV-2. SNG001 has been shown to activate, enhance and extend the innate, antiviral defense as measured using biomarkers in these patients. Synairgen's drug has previously been shown to be effective against SARS-1 and MERS, and based on Phase 2 data appears more effective than Gilead's Remdesivir. Insights from industry players, clinicians and KOLs support our views.
Compelling risk/reward: We detail the risks facing Synairgen throughout this note, but given the strong data in Phase 2, we place the chance of Phase 3 success at 70%, slightly above the industry average. The question then becomes what value can be placed on a drug that treats the vulnerable and could enable a return to the old normal? Our Bull case extends to £50/sh based on the valuations of Moderna/BioNTech with a need for SNG001 whether or not the vaccines prove successful.
*****************************************
My note - This message is for anyone here who would like to consider long term hold of synairgen. COPD treatment potential is huge if ready to hold
Numis
Synairgen (Buy, TP: 990p) World-class asset to treat SARS-CoV-2
Synairgen has developed an inhaled version of interferon-beta (SNG001), that has recently proven highly effective for the treatment of SARS-CoV-2 (COVID-19) in a gold-standard, placebo-controlled Phase 2 study conducted across leading respiratory centres in the UK. The drug is widely known to enhance the innate immune response, which is the body's first line of defense against viruses, and is unique in being delivered directly into the lungs, where respiratory viruses initally take hold.
Subject to funding we expect a pivotal trial to start before the end of the year, and if the Phase 2 data is replicated in a larger Phase 3 study, SNG001 would be the most effective treatment for SARS-CoV-2 with future potential to treat various seasonal, endemic, and pandemic threats.
We initiate coverage with a Buy rating and 990p price target (6x upside) derived from a base (70%)/bear (30%) scenario analysis, which in our view represents a very compelling risk/reward proposition.
Download World-class asset to treat SARS-CoV-2
(36 pages)
Prospects have been transformed: The ongoing SARS-CoV-2 pandemic has demonstrated the threat posed by respiratory viruses. In a matter of months, capabilities have evolved to be able to test for, track and isolate infected patients to protect the vulnerable, yet numbers of cases, hospitalisations and sadly deaths, are still rising. We expect this capability will be retained, and that a therapeutic market and infrastructure for identifying and treating SARS-CoV-2 (and other respiratory viruses) has been rapidly created, that could be worth $20bn/year, a fraction of the costs of global lockdown.
Innately attractive: The innate immune response is known to weaken with age and illness (Source: WHO). The elderly and those with underlying conditions are the most vulnerable to SARS-CoV-2. SNG001 has been shown to activate, enhance and extend the innate, antiviral defense as measured using biomarkers in these patients. Synairgen's drug has previously been shown to be effective against SARS-1 and MERS, and based on Phase 2 data appears more effective than Gilead's Remdesivir. Insights from industry players, clinicians and KOLs support our views.
Compelling risk/reward: We detail the risks facing Synairgen throughout this note, but given the strong data in Phase 2, we place the chance of Phase 3 success at 70%, slightly above the industry average. The question then becomes what value can be placed on a drug that treats the vulnerable and could enable a return to the old normal? Our Bull case extends to £50/sh based on the valuations of Moderna/BioNTech with a need for SNG001 whether or not the vaccines prove successful.
*****************************************
My note - This message is for anyone here who would like to consider long term hold of synairgen. COPD treatment potential is huge if ready to hold
First time a world prestigious Journal today has come out openly criticising leadership handling of covid. Worth a read as board is silent.
https://www.nejm.org/doi/full/10.1056/NEJMe2029812
Novacyt does not have scandals, poor management, burgeoning debt and most important small number shares compared to Glen. Wish you all had picked up some instead of waiting on Glen, BP, Boho to go up.
Biotech and medical companies get hammered during research phase when there is negative news for years on end. When they get a successful product out the market rewards by giving it a higher PE. Reversal are rapid therefore.
Those interested DYOR and buy synairgen for a double from here by December. Take a bold punt by dumping some non movers even if at loss. Let's discuss in december or we'll before that.
If POTUS recovers from Covid without any issues there will be no end to his theory of no need for masks, social distancing etc. His flock will use that as evidence to break all rules. Tough times ahead.
Nobody is talking of Joe Biden who he was close to just 2 nights ago during the debate and shouting at. If Biden also tests positive markets will dive
Some articles to explain why Glencore is not having any traction whatsoever.
Coal heavy investment was a horrible one which will bite as it is a white elephant. No movement on scandal front will be a millstone around Glenda's neck.
Glad I dumped Glen way back at 320 level when they announced drop in outlook of productions. Ken did so at 180 to 190 level.
https://www.google.com/amp/s/www.hellenicshippingnews.com/glencore-trafigura-to-make-managed-exit-from-coal-businesses/amp/
https://www.thearmchairtrader.com/glencore-stock-price-forecast/
https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/922556
Apologies for negative vibe re Glenda from long time holders point of view who want it to croo 220p. Just putting info out FBO PFen